Mesoblast Limited vs Oklo Inc — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while Oklo Inc trades at $47.94 (market cap $8.74B). The key difference: Oklo Inc is far larger — about 4× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Oklo Inc nearer its low. Which is the better fit depends on your goals.
| MESO | OKLO | |
|---|---|---|
Market Cap | $2.21B | $8.74B |
Sector | Technology | Technology |
52-Week High | $20.96 | $174.14 |
52-Week Low | $12.88 | $36.84 |
Enterprise Value | $2.21B | $6.28B |
Trailing returns across standard periods
Latest headlines on both assets
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →